| P50 | author | Benjamin A. Lipsky | Q37830281 |
| P2093 | author name string | A Berendt | |
| | I Byren | |
| | E J G Peters | |
| | C Hoey | |
| P2860 | cites work | Osteomyelitis | Q33205211 |
| | Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up | Q33859977 |
| | Antibiotic beads in the treatment of diabetic pedal osteomyelitis | Q33902716 |
| | Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection | Q33981858 |
| | Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate | Q34284305 |
| | Diagnosis and treatment of diabetic foot infections | Q34357233 |
| | The diagnosis of osteomyelitis in diabetes using erythrocyte sedimentation rate: a pilot study | Q34419395 |
| | Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters | Q34459145 |
| | Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients with diabetes and suspected osteomyelitis of the foot | Q34948171 |
| | Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases | Q35688447 |
| | Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis | Q35745888 |
| | Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies | Q35777069 |
| | Controversies in diagnosing and managing osteomyelitis of the foot in diabetes | Q35861300 |
| | Pharmacodynamics of antimicrobial drugs | Q35861670 |
| | Prosthetic-joint infections | Q35917924 |
| | Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? | Q36102461 |
| | Penetration of clindamycin into decubitus ulcers | Q36474319 |
| | Oral antimicrobial therapy for diabetic foot osteomyelitis | Q36630236 |
| | Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment | Q36835821 |
| | Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. | Q37149371 |
| | Daptomycin in bone and joint infections: a review of the literature | Q37319460 |
| | Nuclear medicine and diabetic foot infections | Q37336252 |
| | Current concepts in imaging diabetic pedal osteomyelitis | Q37336294 |
| | Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers | Q37364923 |
| | Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations | Q37409468 |
| | Current concepts review: diagnostic imaging of the diabetic foot | Q37503855 |
| | Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists | Q37537565 |
| | Puncture wounds: normal laboratory values in the face of severe infection in diabetics and non-diabetics | Q39437159 |
| | Vancomycin concentrations in infected and noninfected human bone | Q39832249 |
| | Osteomyelitis: A Review of Clinical Features, Therapeutic Considerations and Unusual Aspects | Q39986155 |
| | Once-daily dosing of aminoglycosides: review and recommendations for clinical practice | Q41530531 |
| | Osteomyelitis of the foot in diabetic patients | Q41683213 |
| | The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb | Q43586074 |
| | Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis | Q43815771 |
| | Conservative management of osteomyelitis in the feet of diabetic patients | Q44006443 |
| | Acute renal failure after local gentamicin treatment in an infected total knee arthroplasty. | Q44176075 |
| | Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics | Q44380332 |
| | MRSA-infections-treatment with intraoperatively produced gentamycin-vancomycin PMMA beads | Q44899938 |
| | High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion | Q44991015 |
| | Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials | Q46617403 |
| | Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study | Q46815624 |
| | Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin | Q46832064 |
| | Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers | Q46915090 |
| | Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. | Q50920358 |
| | Epidemiology and prevalence of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis in patients with diabetic foot ulcers: focus on the differences between species isolated from individuals with ischemic vs. neuropathic foot ul | Q54491953 |
| | Probe-to-Bone Test for Diagnosing Diabetic Foot Osteomyelitis: Reliable or relic? | Q57543727 |
| | Validation of the Infectious Diseases Society of America's Diabetic Foot Infection Classification System | Q57543736 |
| | Risk Factors for Foot Infections in Individuals With Diabetes | Q57543754 |
| | 'Sausage toe': a reliable sign of underlying osteomyelitis | Q58842299 |
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacotherapy | Q701216 |
| P304 | page(s) | 3033-3047 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Pharmacotherapy of diabetic foot osteomyelitis | |
| P478 | volume | 10 | |